Old Web
English
Sign In
Acemap
>
Paper
>
ATIM-41. PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) For Newly Diagnosed Glioblastoma
ATIM-41. PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) For Newly Diagnosed Glioblastoma
2018
Manmeet S. Ahluwalia
David A. Reardon
Ajay Abad
William T. Curry
Eric T. Wong
David M. Peereboom
Ahmed Belal
Jingxin Qiu
Kathleen Mogensen
Cathy Schilero
Danielle Casucci
Laszlo Mechtler
Erik Uhlmann
Michael J. Ciesielski
Robert A. Fenstermaker
Keywords:
Survivin
Karnofsky Performance Status
Temozolomide
Glioblastoma
Immunology
Pharmaceutical Adjuvants
Progression-free survival
O-6-methylguanine-DNA methyltransferase
Phases of clinical research
Oncology
Internal medicine
Medicine
newly diagnosed
tumor cells
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
4
Citations
NaN
KQI
[]